Store-dependent Ca2+ entry in endothelial progenitor cells as a perspective tool to enhance cell-based therapy and adverse tumour vascularization

F. Moccia, S. Dragoni, F. Lodola, E. Bonetti, C. Bottino, G. Guerra, U. Laforenza, V. Rosti, F. Tanzi

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Endothelial progenitor cells (EPCs) have recently been employed in cell-based therapy (CBT) to promote neovascularization and regeneration of ischemic organs, such as heart and limbs. Furthermore, EPCs may be recruited from bone marrow by growing tumors to drive the angiogenic switch through physical engrafting into the lumen of nascent vessels or paracrine release of pro-angiogenic factors. CBT is hampered by the paucity of EPCs harvested from peripheral blood and suffered from several pitfalls, including the differentiation outcome of transplanted cells and low percentage of engrafted cells. Therefore, CBT will benefit from a better understanding of the signal transduction pathway(s) which govern(s) EPC homing, proliferation and incorporation into injured tissues. At the same time, this information might outline alternative molecular targets to combat tumoral neovascularization. We have recently found that storeoperated Ca2+ entry, a Ca 2+-permeable membrane pathway that is activated upon depletion of the inositol-1,4,5-trisphosphate-sensitive Ca2+ pool, is recruited by vascular endothelial growth factor to support proliferation and tubulogenesis in human circulating endothelial colony forming cells (ECFCs). ECFCs are a subgroup of EPCs that circulate in the peripheral blood of adult individuals and are able to proliferate and differentiate into endothelial cells and form capillary networks in vitro and contribute to neovessel formation in vivo. The present review will discuss the relevance of SOCE to ECFC-based cell therapy and will address the pharmacological inhibition of storedependent Ca2+ channels as a promising target for anti-angiogenic treatments.

Original languageEnglish
Pages (from-to)5802-5818
Number of pages17
JournalCurrent Medicinal Chemistry
Volume19
Issue number34
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Endothelial cells
Cell- and Tissue-Based Therapy
Tumors
Neoplasms
Blood
Inositol 1,4,5-Trisphosphate
Angiogenesis Inducing Agents
Signal transduction
Vascular Endothelial Growth Factor A
Cell proliferation
Regeneration
Signal Transduction
Extremities
Endothelial Cells
Bone Marrow
Cell Proliferation
Endothelial Progenitor Cells
Pharmacology
Bone
Switches

Keywords

  • Antiangiogenic drugs
  • Calcium signalling
  • Cardiovascular diseases
  • Cellbased therapy
  • Endothelial progrenitor cells
  • Neovascularisation
  • Orai1
  • Stim1
  • Store-operated calcium entry
  • Tumour

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Store-dependent Ca2+ entry in endothelial progenitor cells as a perspective tool to enhance cell-based therapy and adverse tumour vascularization. / Moccia, F.; Dragoni, S.; Lodola, F.; Bonetti, E.; Bottino, C.; Guerra, G.; Laforenza, U.; Rosti, V.; Tanzi, F.

In: Current Medicinal Chemistry, Vol. 19, No. 34, 12.2012, p. 5802-5818.

Research output: Contribution to journalArticle

Moccia, F. ; Dragoni, S. ; Lodola, F. ; Bonetti, E. ; Bottino, C. ; Guerra, G. ; Laforenza, U. ; Rosti, V. ; Tanzi, F. / Store-dependent Ca2+ entry in endothelial progenitor cells as a perspective tool to enhance cell-based therapy and adverse tumour vascularization. In: Current Medicinal Chemistry. 2012 ; Vol. 19, No. 34. pp. 5802-5818.
@article{110f561de040493aae338332f2d253a8,
title = "Store-dependent Ca2+ entry in endothelial progenitor cells as a perspective tool to enhance cell-based therapy and adverse tumour vascularization",
abstract = "Endothelial progenitor cells (EPCs) have recently been employed in cell-based therapy (CBT) to promote neovascularization and regeneration of ischemic organs, such as heart and limbs. Furthermore, EPCs may be recruited from bone marrow by growing tumors to drive the angiogenic switch through physical engrafting into the lumen of nascent vessels or paracrine release of pro-angiogenic factors. CBT is hampered by the paucity of EPCs harvested from peripheral blood and suffered from several pitfalls, including the differentiation outcome of transplanted cells and low percentage of engrafted cells. Therefore, CBT will benefit from a better understanding of the signal transduction pathway(s) which govern(s) EPC homing, proliferation and incorporation into injured tissues. At the same time, this information might outline alternative molecular targets to combat tumoral neovascularization. We have recently found that storeoperated Ca2+ entry, a Ca 2+-permeable membrane pathway that is activated upon depletion of the inositol-1,4,5-trisphosphate-sensitive Ca2+ pool, is recruited by vascular endothelial growth factor to support proliferation and tubulogenesis in human circulating endothelial colony forming cells (ECFCs). ECFCs are a subgroup of EPCs that circulate in the peripheral blood of adult individuals and are able to proliferate and differentiate into endothelial cells and form capillary networks in vitro and contribute to neovessel formation in vivo. The present review will discuss the relevance of SOCE to ECFC-based cell therapy and will address the pharmacological inhibition of storedependent Ca2+ channels as a promising target for anti-angiogenic treatments.",
keywords = "Antiangiogenic drugs, Calcium signalling, Cardiovascular diseases, Cellbased therapy, Endothelial progrenitor cells, Neovascularisation, Orai1, Stim1, Store-operated calcium entry, Tumour",
author = "F. Moccia and S. Dragoni and F. Lodola and E. Bonetti and C. Bottino and G. Guerra and U. Laforenza and V. Rosti and F. Tanzi",
year = "2012",
month = "12",
doi = "10.2174/092986712804143240",
language = "English",
volume = "19",
pages = "5802--5818",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "34",

}

TY - JOUR

T1 - Store-dependent Ca2+ entry in endothelial progenitor cells as a perspective tool to enhance cell-based therapy and adverse tumour vascularization

AU - Moccia, F.

AU - Dragoni, S.

AU - Lodola, F.

AU - Bonetti, E.

AU - Bottino, C.

AU - Guerra, G.

AU - Laforenza, U.

AU - Rosti, V.

AU - Tanzi, F.

PY - 2012/12

Y1 - 2012/12

N2 - Endothelial progenitor cells (EPCs) have recently been employed in cell-based therapy (CBT) to promote neovascularization and regeneration of ischemic organs, such as heart and limbs. Furthermore, EPCs may be recruited from bone marrow by growing tumors to drive the angiogenic switch through physical engrafting into the lumen of nascent vessels or paracrine release of pro-angiogenic factors. CBT is hampered by the paucity of EPCs harvested from peripheral blood and suffered from several pitfalls, including the differentiation outcome of transplanted cells and low percentage of engrafted cells. Therefore, CBT will benefit from a better understanding of the signal transduction pathway(s) which govern(s) EPC homing, proliferation and incorporation into injured tissues. At the same time, this information might outline alternative molecular targets to combat tumoral neovascularization. We have recently found that storeoperated Ca2+ entry, a Ca 2+-permeable membrane pathway that is activated upon depletion of the inositol-1,4,5-trisphosphate-sensitive Ca2+ pool, is recruited by vascular endothelial growth factor to support proliferation and tubulogenesis in human circulating endothelial colony forming cells (ECFCs). ECFCs are a subgroup of EPCs that circulate in the peripheral blood of adult individuals and are able to proliferate and differentiate into endothelial cells and form capillary networks in vitro and contribute to neovessel formation in vivo. The present review will discuss the relevance of SOCE to ECFC-based cell therapy and will address the pharmacological inhibition of storedependent Ca2+ channels as a promising target for anti-angiogenic treatments.

AB - Endothelial progenitor cells (EPCs) have recently been employed in cell-based therapy (CBT) to promote neovascularization and regeneration of ischemic organs, such as heart and limbs. Furthermore, EPCs may be recruited from bone marrow by growing tumors to drive the angiogenic switch through physical engrafting into the lumen of nascent vessels or paracrine release of pro-angiogenic factors. CBT is hampered by the paucity of EPCs harvested from peripheral blood and suffered from several pitfalls, including the differentiation outcome of transplanted cells and low percentage of engrafted cells. Therefore, CBT will benefit from a better understanding of the signal transduction pathway(s) which govern(s) EPC homing, proliferation and incorporation into injured tissues. At the same time, this information might outline alternative molecular targets to combat tumoral neovascularization. We have recently found that storeoperated Ca2+ entry, a Ca 2+-permeable membrane pathway that is activated upon depletion of the inositol-1,4,5-trisphosphate-sensitive Ca2+ pool, is recruited by vascular endothelial growth factor to support proliferation and tubulogenesis in human circulating endothelial colony forming cells (ECFCs). ECFCs are a subgroup of EPCs that circulate in the peripheral blood of adult individuals and are able to proliferate and differentiate into endothelial cells and form capillary networks in vitro and contribute to neovessel formation in vivo. The present review will discuss the relevance of SOCE to ECFC-based cell therapy and will address the pharmacological inhibition of storedependent Ca2+ channels as a promising target for anti-angiogenic treatments.

KW - Antiangiogenic drugs

KW - Calcium signalling

KW - Cardiovascular diseases

KW - Cellbased therapy

KW - Endothelial progrenitor cells

KW - Neovascularisation

KW - Orai1

KW - Stim1

KW - Store-operated calcium entry

KW - Tumour

UR - http://www.scopus.com/inward/record.url?scp=84871278766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871278766&partnerID=8YFLogxK

U2 - 10.2174/092986712804143240

DO - 10.2174/092986712804143240

M3 - Article

C2 - 22963562

AN - SCOPUS:84871278766

VL - 19

SP - 5802

EP - 5818

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 34

ER -